Diarylspiro[2.4]heptenes as orally active, highly selective cyclooxygenase-2 inhibitors: Synthesis and structure-activity relationships

Journal of Medicinal Chemistry

Volumn 39, Issue 1, 1996, Pages 253-266

  Huang, Horng Chih ^a   Li, James J ^a   Garland, Danny J ^a   Chamberlain, Timothy S ^a   Reinhard, Emily J ^a   Manning, Robert E ^a   Seibert, Karen ^a   Koboldt, Carol M ^a   Gregory, Susan A ^a   Anderson, Gary D ^a   Veenhuizen, Amy W ^a   Zhang, Yan ^a   Perkins, William E ^a   Burton, Earl G ^a   Cogburn, J Nita ^a   Isakson, Peter C ^a   Reitz, David B ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 FLUOROPHENYL) 2 [(4 METHYLSULFONYL)PHENYL]CYCLOPENTENE; 4 [6 (3 CHLORO 4 METHOXYPHENYL)SPIRO[2.4]HEPT 5 EN 5 YL]BENZENESULFONAMIDE; 5 (3,5 DICHLORO 4 METHOXYPHENYL) 6 [4 (METHYLSULFONYL)PHENYL]SPIRO[2.4]HEPT 5 ENE; 5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; ALKENE DERIVATIVE; CYCLOALKENE; MESYLIC ACID DERIVATIVE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN SYNTHASE INHIBITOR; SC 58231; SULFONAMIDE; UNCLASSIFIED DRUG;

ADJUVANT DISEASE; ANALGESIC ACTIVITY; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; DRUG BIOAVAILABILITY; DRUG DEVELOPMENT; DRUG HALF LIFE; DRUG SELECTIVITY; DRUG SYNTHESIS; EDEMA; GASTROINTESTINAL TOXICITY; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; STRUCTURE ACTIVITY RELATION;

ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; CARRAGEENAN; CYCLOOXYGENASE INHIBITORS; EDEMA; HUMANS; INTESTINES; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; RATS; RATS, INBRED LEW; RATS, SPRAGUE-DAWLEY; SPIRO COMPOUNDS; STOMACH; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; SULFONES;

EID: 13344261416     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm950664x     Document Type: Article

References (37)

1. Lombardino, G. Nonsteroidal Antiinflammatory Drugs; Wiley Interscience, John Wiley & Sons: New York, 1985.
2. Allison, M. C.; Howatson, A. G.; Torrance, C. J.; Lee, F. D.; Russell, R. I. G. Gastrointestinal Damage Associated with the Use of Non-Steroidal Antiinflammatory Drugs. N. Engl. J. Med. 1992, 327, 749-754.
3. Clive, D. M.; Stoff, J. S. Renal Syndromes Associated with Nonsteroidal Antiinflammatory Drugs. N. Engl. J. Med. 1984, 310, 563-572.
4. Pirson, Y.; Van Ypersele de Strihou, C. Renal Side Effects of Nonsteroidal Anti-Inflammatory Drugs: Clinical Relevance. Am. J. Kidney Dis. 1986, 8, 337-344.
5. Vane, J. R. Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-Like Drugs. Nature (New Biol.) 1971, 231, 232-235.
6. Smith, J. B.; Willis, A. L. Aspirin Selectively Inhibits Prostaglandin Production in Human Platelets. Nature (New Biol.) 1971, 231, 235-237.
7. Hla, T.; Neilson, K. Human Cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 7384-7388.
8. Xie, W.; Chipman, J. G.; Robertson, D. L.; Erikson, R. L.; Simmons, D. L. Expression of a Mitogen-Response Gene Encoding Prostaglandin Synthase Is Regulated by mRNA Splicing. Proc. Natl. Acad. Sci. U.SA. 1991, 88, 2692-2696.
9. Kujubu, D. A.; Fletcher, B. S.; Varnum, C.; Lim, R. W.; Herschman, H. TIS10, a Phorbol Ester Tumor Promoter-Inducible mRNA from Swiss 3T3 Cells, Encodes a Novel Prostaglandin Synthase/Cyclooxygenase Homologue. J. Biol. Chem. 1991, 266, 12866-12872.
10. The expression of this enzyme has been shown to be induced by cytokines and endotoxins; see: Masferrer, J. L.; Seibert, K.; Zweifel, B.; Needleman, P. Endogenous Glucocorticoids Regulate an Inducible Cyclooxygenase Enzyme. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 3917-3921.
11. Gans, K. R.; Galbraith, W.; Roman, R. J.; Haber, S. B.; Kerr, J. S.; Schmidt, W. K.; Smith, C.; Hewes, W. E.; Ackerman, N. R. Anti-inflammatory and Safety Profile of DuP 697, a Novel Orally Effective Prostaglandin Synthesis Inhibitor. J. Pharmacol. Exp. Ther. 1989, 254, 180-187.
12. Futaki, N.; Yoshikawa, K.; Hamasaka, Y.; Arai, I.; Higuchi, S.; Iizuka, H.; Otomo, S. NS-398, A Novel Non-Steroidal Anti-Inflammatory Drug with Potent Analgesic and Antipyretic Effects, Which Causes Minimal Stomach Lesions. Gen. Pharmacol. 1993, 24, 105-110.
13. Isakson, P.; Seibert, K.; Masferrer, J.; Salvemini, D.; Lee, L.; Needleman, P. Discovery of a Better Aspirin. Ninth International Conference on Prostaglandins and Related Compounds, Florence, Italy, June 1994.
14. Futaki, N.; Takahashi, S.; Yokoyama, M.; Arai, I.; Huguchi, S.; Otomo, S. NS-398, a New Anti-inflammatory Agent, Selectively Inhibits Prostaglandin G/H Synthase/Cyclooxygenase (COX-2) Activity In Vitro. Prostaglandins 1994, 47, 55-59.
15. Masferrer, J. L.; Zweifer, B. S.; Manning, P. T.; Hauser, S. D.; Leahy, K. M.; Smith, W. G.; Isakson, P. C.; Seibert, K. Selective Inhibition of Inducible Cyclooxygenase 2 In Vivo Is Antiinflammatory and Nonulcerogenic. Proc Natl. Acad. Sci. U.S.A. 1994, 91, 3228-3232.
16. Copeland, R. A.; Williams, J. M.; Giannaras, J., Nurnberg, S.; Covington, M.; Pinto, D.; Pick, S.; Trzaskos, J. M. Mechanism of Selective Inhibition of the Inducible Isoform of Prostaglandin G/H Synthase. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 11202-1120.
17. Copeland, R. A.; Williams, J. M.; Rider, N. L.; Van Dyk, D. E.; Giannaras, J.; Nurnberg, S.; Covington, M.; Pinto, D.; Magolda, R. L.; Trzaskos, J. M. Selective Time Dependent Inhibition of Cyclooxygenase-2. Med. Chem. Res. 1995, 5, 384-393.
18. Schoen, R. T.; Vender, R. J. Mechanisms of Nonsteroidal Antiinflammatory Drug-Induced Gastric Damage. Am. J. Med. 1989, 86, 449-458.
19. Reitz, D. B.; Li, J. J.; Norton, M. B.; Reinhard, E. J.; Huang, H.-C.; Penick, M. A.; Collins, J. T.; Garland, D. J.; Seibert, K.; Kobold, C. M.; Gregory, S.; Veenjuizen, A.; Zhang, Y.; Isakson, P. Novel 1,2-Diarylcyclopentenes Are Selective, Potent and Orally Active Cyclooxygenase Inhibitors. Med. Chem. Res. 1995, 5, 351-363.
20. Reitz, D. B.; Li, J. J.; Norton, M. B.; Reinhard, E. J.; Collins, J. T.; Anderson, G. D.; Gregory, S.; Kobold, C. M.; Perkins, W. E.; Seibert, K.; Isakson, P. C. Selective Cyclooxygenase Inhibitors: Novel 1,2-Diarylcyclopentenes Are Potent and Orally Active COX-2 Inhibitors. J. Med. Chem. 1994, 37, 3878-3881.
21. Reitz, D. B.; Li, J. J.; Norton, M. B.; Reinhard, E. J.; Penick, M. A.; Collins, J. T.; Logusch, E. W.; Garland, D. J.; Chamberlain, T. S.; Huang, H.-C.; Isakson, P.; Seibert, K.; Kobold, C.; Gregory, S.; Veenjuizen, A.; Zhang, Y.; Anderson, G.; Perkins, W.; Casler, J.; Ponte, C. 208th National ACS Meeting, 1994; MEDI-271.
22. Reitz, D. B.; Huang, H.-C.; Li, J.; Garland, D. J.; Manning, R. E.; Anderson, G. D.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K. Isakson, P. C. Selective Cyclooxygenase Inhibitors: Novel 4-Spiro 1,2-Diarylcyclopentenes Are Potent and Orally Active COX-2 Inhibitors. Bioorg. Med. Chem. Lett. 1995, 5, 867-872.
23. Vijayaraghavan, S. T.; Balasubramanina, T. R. Synthesis of 3,4-Diaryl-2(5H)-Furanones. Indian J. Chem. 1986, 25B, 760-761.
24. Lerstrup, K.; Bailey, A.; McCullough, R.; Mays, M.; Cowan, D. The Synthesis and Study of New Selenium and Tellurium Heterocyctic π-Donors. Synth. Metals 1987, 19, 647-652.
25. For a review, see: Pons, J.-M.; Santelli, M. Reductions Promoted by Low Valent Transition Metal Complexes in Organic Synthesis. Tetrahedron 1988, 44, 4295-4312.
26. Huang, H.-C.; Reinhard, E. J.; Reitz, D. B. A Novel One-Pot Conversion of Methyl Sulfones to Sulfonamides. Tetrahedron. Lett. 1994, 39, 7201-7204.
27. The enone compounds were prepared sequentially according to the following procedures: (a) Walshe, N. D. A.; Goodwin, G. B. T.; Smith, G. C.; Woodward, F. E. Acetone Trimethylsilyl Enol Ether. Org. Synth. 1986, 65, 1-5. (b) Mukaiyama, T.; Narasaka, K. 3-Hydroxy-3-Methyl-1-Phenyl-1-Butanone by Crossed Aldol Reaction. Org. Synth. 1986, 65, 6-11.
28. The enone compounds were prepared sequentially according to the following procedures: (a) Walshe, N. D. A.; Goodwin, G. B. T.; Smith, G. C.; Woodward, F. E. Acetone Trimethylsilyl Enol Ether. Org. Synth. 1986, 65, 1-5. (b) Mukaiyama, T.; Narasaka, K. 3-Hydroxy-3-Methyl-1-Phenyl-1-Butanone by Crossed Aldol Reaction. Org. Synth. 1986, 65, 6-11.
29. Narasaka, K. 3-Dimethyl-1,5-Diphenylpentane-1,5-Dione. Org. Synth. 1986, 65, 12-15.
30. Gierse, J. K.; Hauser, S. D.; Creely, D. P.; Koboldt, C.; Rangwala, S. H.; Isakson, P. C.; Seibert, K. Expression and Selective Inhibition of the Constitutive and Inducible Forms of Human Cyclooxygenase. Biochem. J. 1995, 305, 479-484.
31. 50 values (COX-2/COX-1) of 0.01 μM/0.8 μM and 0.1 μM/> 10 μM, respectively.
32. Seibert, K.; Masferrer, J. L.; Hauser, S. D.; Isakson, P. C. 1994. Pharmacological and Biochemical Demonstration of the Role of Cyclooxygenase 2 in Inflammation and Pain. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 12013-12017.
33. Winter, C. A.; Risley, E. A.; Nuss, G. W. Carrageenan-Induced Edema in Hind Paw of the Rat as an Assay for Antiinfiammatory Drugs. Proc. Soc. Exp. Biol. Med. 1962, 111, 544-547.
34. The advantages of this substitution pattern were first realized in another system; see: Talley, J. J.; Carter J. S.; Graneto, M. J. Unpublished results.
35. Reitz, D. B.; Manning, R. E.; Huang, H.-C.; Li, J. U.S. Patent 5 393 790, 1995.
36. Jaffee, B. D.; Kerr, J. S.; Jones, E. A.; Giannaras, J. V.; McGowan, M.; Aekerman, N. R. The Effect of Immunomodulating Drugs on Adjuvant-Induced Arthritis in Lewis Rats. Agents Actions 1989, 27, 344-346.
37. Sedman, A. T.; Wagner, J. G. CSTRIP, a Fortran IV Computer Program for Obtaining Initial Polyexponential Parameter Estimates. J. Pharm. Sci. 1976, 65, 1006-1010.